Press release
Global Cancer Peptide Drug Market To Surpass USD 16 Billion By 2024
* Fundamentals of Peptide Therapeutics
* Peptide Therapeutics by Applications & Indications
* Peptides Clinical Trials Insight by Phase, Indication & Company
* Insight on 688 Peptide Drugs in Clinical Trials
* Clinical & Patent Insight on 119 Marketed Peptides
* Future Peptide Therapeutics Market Outlook
Download Report Sample Weblink:
http://pnspharma.com/buy-report.php?reporttitle=Global-Peptide-Therapeutics-Market-%26-Clinical-Trials-Insight-2022
For Report Sample Contact: rajesh@pnspharma.com
Table of Contents
1. A Revolution of Peptide Therapeutics
1.1 Peptides as Drug Candidates
1.2 Necessity of Peptide Therapeutics
2. Cusp of Small Molecules & Proteins
2.1 Peptides v/s Small Molecules
2.2 Peptides v/s Protein Biologics
3. Fundamentals of Peptide Therapeutics
3.1 Rational Design for Novel Peptides
3.2 Aspects of Regulatory Approvals
4. Peptide Therapeutics by Applications
4.1 Application of Peptides in Imaging
4.2 Application of Peptides in Diseases
5. Peptide Therapeutics in Metabolic Disorder
5.1 Prologue Metabolic Disorders
5.2 Approved Peptide Drugs for Metabolic Disorders
5.3 Market of Metabolic Peptides
6. Peptide Therapeutics in Cancer
6.1 Prologue to Cancer
6.2 Approved Peptide Drugs in Cancer Therapeutics
6.3 Market of Cancer Peptides
7. Peptide Therapeutics in Cardiovascular
7.1 Prologue to Cardiovascular Diseases
7.2 Approved Peptide Drugs in Cardiovascular Diseases
7.3 Market of Cardiac Peptides
8. Peptide Therapeutics in HIV & Infections
8.1 Prologue to Infections
8.2 Approved Peptide Therapeutics in Infections
8.3 Market of Anti-Infectious Peptides
9. Peptide Therapeutics in CNS Disorders
9.1 Prologue to CNS Disorders
9.2 Neuropeptides Drug Delivery to CNS
9.3 Future Market Potential
10. Global Peptide Therapeutics Market
10.1 Prologue to the Peptide Market
10.2 Peptide Market by Application
11. Global Peptide Market by Administration
11.1 Current Trends in Route of Administration
11.2 Current Trends over the Peptide Products
12. Global Peptides Clinical Trials Overview
12.1 Cyclic Peptides
12.2 Depsipeptides
12.3 Dipeptides
12.4 Glucagon-Like Peptides
12.5 Lipopeptides
12.6 Natriuretic Peptides
12.7 Neuropeptides Peptides
12.8 Oligopeptides
12.9 Opioid Peptides
12.10 Peptides
12.11 Peptide Hormones
12.12 Peptide Fragments
12.13 Multiple Peptides
13. Global Peptide Market by Region
13.1 North America
13.2 Europe
13.3 Asia
14. Global Peptide Market Dynamics
14.1 Favorable Parameters
14.2 Challenges
15. Future Peptide Therapeutics Market Outlook
15.1 Future Trends in Peptide Therapeutics
15.2 Future Opportunities of Peptides Therapeutics
16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company
16.1 Research till Preregistration
16.2 Marketed
17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company
17.1 Preclinical till Preregistration
17.2 Marketed
18. Dipeptides Clinical Trials Insight by Phase, Indication & Company
18.1 Preclinical till Registered
18.2 Marketed
19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company
19.1 Preclinical till Phase-I
20. Glucagon-Like Peptides Clinical Trials Insight by Phase, Indication & Company
20.1 Resarch till Phase-III
20.2 Marketed
21. Lipopeptides Clinical Trials Insight by Phase, Indication & Company
21.1 Preclinical till Phase-II
22. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company
22.1 Preclinical till Phase-III
22.2 Marketed
23. Neuropeptides Clinical Trials Insight by Phase, Indication & Company
23.1 Preclinical till Phase-III
23.2 Marketed
24. Oligopeptides Clinical Trials Insight by Phase, Indication & Company
24.1 Preclinical till Registered
24.2 Marketed
25. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company
25.1 Preclinical till Preregistration
25.2 Marketed
26. Peptides Clinical Trials Insight by Phase, Indication & Company
26.1 Research till Registered
26.2 Marketed
27. Peptide Antibiotics Clinical Trials Insight by Phase, Indication & Company
27.1 Research
28. Peptide Aptamers Clinical Trials Insight by Phase, Indication & Company
28.1 Preclinical
29. Peptide Hormones Clinical Trials Insight by Phase, Indication & Company
29.1 Research till Registered
29.2 Marketed
30. Peptide Fragments Clinical Trials Insight by Phase, Indication & Company
30.1 Research till Preregistration
30.2 Marketed
31. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company
31.1 Research till Preregistration
31.2 Marketed
32. Competitive Landscape
32.1 Amgen
32.2 Amylin Pharmaceuticals
32.3 Apitope Technology
32.4 BioPartners
32.5 BiondVax Pharmaceuticals Ltd
32.6 Boehringer Ingelheim
32.7 Circassia
32.8 Corden Pharma (Peptisyntha)
32.9 Eli Lily
32.10 Galena Biopharmaceuticals
32.11 GlaxoSmithKline
32.12 Hyperion Therapeutics
32.13 ImmunoCellular Therapeutics
32.14 Ipsen
32.15 Lonza
32.16 Merck
32.17 NovoNordisk
32.18 Par Pharmaceuticals
32.19 PeptiDream
32.20 Roche
32.21 Sanofi
32.22 Tarix Pharmaceuticals
Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
Figure 2-2: Layout of Advantages of Peptide Drugs
Figure 3-1: Classification Based over the Sources of Peptide
Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
Figure 4-1: Diagrammatic Representation of the Peptidic Probe
Figure 4-2: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
Figure 5-1: Layout of Metabolic Syndrome Leading to Several Diseases
Figure 5-2: Global - Top 10 Countries with Diabetes Burden (Million), 2030
Figure 5-3: Obesity - Estimated Prevalence by Country (2025)
Figure 5-4: US– GLP-1 Agonist Drugs Cost Comparison (US$)
Figure 5-5: Lantus – Monthly Cost Comparison by Country (US$)
Figure 5-6: Global - Metabolic Disorders Peptide Drug Market (US$ Billion)
Figure 5-7: Victoza - GLP-1 Value Market Percentage Share of Total Diabetic Care Market
Figure 6-1: Global - All Cancer Rates Cases per 100,000 People by Top 10 Country
Figure 6-2: Global - Cancer Peptide Therapeutics Market (US$ Billion), 2014 & 2020
Figure 6 3: Global - Velcade Market Sales (US$ Billion)
Figure 6-4: US – Velcade Sales (US$ Billion), 2016 & 2022
Figure 6-5: Global - Kyprolis Revenues (US$ Billion), 2013 - 2017
Figure 6-6: Global & US - Zoladex Sales (US$ Million), 2016
Figure 7-1: Global & US - Angiomax Sales (US$ Million)
Figure 7-2: Global - Integrilin Sales (US$ Million), 2016
Figure 8-1: Global - Top 10 Leading Causes of Death
Figure 8-2: Global – HIV Prevalence among Varied Regions
Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2016
Figure 9-1: US - Prevalence of Alzheimer’s disease (Millions)
Figure 10-1: Global - Peptide Drug Market (US$ Billion), 2014-2022
Figure 11-1: Therapeutic Peptide Based Drugs over Route of Administration
Figure 12-1: Global – All Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-2: Global - All Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-3: Global - Cyclic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-4: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 12-5: Global - Depsipeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-6: Global - Depsipeptides Peptides Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-7: Global - Dipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-8: Global - Dipeptides Peptides Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-9: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-10: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (Number),
2017 till 2022
Figure 12-11: Global - Lipopeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-12: Global - Lipopeptides Peptides Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-13: Global - Natriuretic Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-14: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-15: Global - Neuropeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-16: Global - Neuropeptides Peptides Clinical Pipeline by Phase (Number),
2017 till 2022
Figure 12-17: Global - Oligopeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-18: Global - Oligopeptides Peptides Clinical Pipeline by Phase (Number),
2017 till 2022
Figure 12-19: Global - Opioid Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-20: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 12-21: Global - Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-22: Global - Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-23: Global - Peptide Hormones Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-24: Global - Peptide Hormones Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 12-25: Global - Peptide Fragments Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-26: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-27: Global - Multiple Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-28: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 14-1: Illustration of Peptide Therapeutics Market Drivers
Figure 14-2: Major Challenges Faced by the Peptide Therapeutics
Figure 15-1: Future Trends of Peptide Therapeutics
PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.
Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Cancer Peptide Drug Market To Surpass USD 16 Billion By 2024 here
News-ID: 1052532 • Views: …
More Releases from PNS Pharma
Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:
o Global Gene Therapy Market Opportunity: > US$ 8 Billion
o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials
o Commercially Available Gene Therapies: 11
o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
o Cancer Accounts For 50% of Global Gene Therapy Trials
Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
Over the years, gene therapy has been highly responsible for decreasing the mortality rate…
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
More Releases for Peptide
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
What's driving the Customized Peptide Synthesis Market Growth? | Key Players are …
The customized peptide synthesis market is projected to generate a revenue of $390.0 million by 2024 as per a recent P&S Intelligence study. The market is being progressively driven by technological innovations, growing burden of cancer and infectious diseases, increasing investments and funding for protein-based research, and rising research activities in synthetic biology.
Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample
There are two main types of products available in the customized peptide synthesis…
Customized Peptide Synthesis Market 2019-2024 by Top Key Players are GenScript, …
Customized peptide synthesis market is forecasted to generate revenue of $390.0 million by 2024. The market is mainly driven by increasing investments and funding for protein-based research, technological innovations, growing burden of cancer and infectious diseases, and increasing research activities in the field of synthetic biology.
Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample
The different types of products available in the customized peptide synthesis market are reagents and equipment. Reagents category is expected…
Peptide Synthesis Market Increasing Demand & Latest Trend with Genscript, AnaSpe …
HTF MI recently introduced United States Peptide Synthesis Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Bachem, PolyPeptide, GL Biochem, Xinbang, Hybio, USVPeptides, Thermofischer, ScinoPharm, Genscript,…
Global Peptide Therapeutics Market: Cancer Treatment to Surface as Key Applicati …
Market Research Reports Search Engine (MRRSE) has been acting as an impressive data source when it comes to evaluating various industrial verticals. The research report titled “Global Peptide Therapeutics Market” offers a clear insight about the Peptide Therapeutics assessed over the global platform. This analysis proves beneficial for readers & new investors who are aiming to enter the market for Peptide Therapeutics in the near future.
Click to Request a Sample:…
Peptide Based Cancer Therapeutics Marke For peptide based cancer therapeutics ov …
About Peptide Based Cancer Therapeutics Market
Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug…
